Back to Search
Start Over
Metabolomic Analysis of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors
- Source :
- Journal of Clinical Medicine, Volume 9, Issue 4, Journal of Clinical Medicine, Vol 9, Iss 1180, p 1180 (2020)
- Publication Year :
- 2020
- Publisher :
- MDPI AG, 2020.
-
Abstract
- Background: Cardiovascular adverse events (CV-AEs) are considered critical complications in chronic myeloid leukemia (CML) patients treated with second- and third-generation tyrosine kinase inhibitors (TKIs). The aim of our study was to assess the correlation between metabolic profiles and CV-AEs in CML patients treated with TKIs. Methods: We investigated 39 adult CML patients in chronic-phase (mean age 49 years, range 24&ndash<br />70 years), with no comorbidities evidenced at baseline, who were consecutively identified with CML and treated with imatinib, nilotinib, dasatinib, and ponatinib. All patients performed Gas-Chromatography-Mass-Spectrometry-based metabolomic analysis and were divided into two groups (with and without CV-AEs). Results: Ten CV-AEs were documented. Seven CV-AEs were rated as 3 according to the Common Toxicity Criteria, and one patient died of a dissecting aneurysm of the aorta. The patients&rsquo<br />samples were clearly separated into two groups after analysis and the main discriminant metabolites were tyrosine, lysine, glutamic acid, ornithine, 2-piperdinecarboxylic acid, citric acid, proline, phenylalanine, threonine, mannitol, leucine, serine, creatine, alanine, and 4-hydroxyproline, which were more abundant in the CV-AE group. Conversely, myristic acid, oxalic acid, arabitol, 4-deoxy rithronic acid, ribose, and elaidic acid were less represented in the CV-AE group. Conclusions: CML patients with CV-AEs show a different metabolic profile, suggesting probable mechanisms of endothelial damage.
- Subjects :
- 0301 basic medicine
cardiovascular adverse events
lcsh:Medicine
Pharmacology
Article
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
hemic and lymphatic diseases
tyrosine kinase inhibitors
medicine
Tyrosine
business.industry
lcsh:R
Chronic myeloid leukemia
Ponatinib
Myeloid leukemia
Imatinib
General Medicine
Ornithine
respiratory tract diseases
Dasatinib
030104 developmental biology
chemistry
Nilotinib
GC-MS metabolomics
030220 oncology & carcinogenesis
business
Tyrosine kinase
medicine.drug
Subjects
Details
- ISSN :
- 20770383
- Volume :
- 9
- Database :
- OpenAIRE
- Journal :
- Journal of Clinical Medicine
- Accession number :
- edsair.doi.dedup.....ffb9117a63ea3a2f9b54635f143c5cff